Kathryn Moore Lab

Studying the crosstalk of inflammation, cardiovascular disease, and RNA biology @NYULangone

[Kathryn Moore Lab @KathrynMooreLab]

@NJTRANSIT Why aren’t email notifications being sent? Why is there no information in the app? Noe we have to go to Twitter/X to figure out what’s going on?!?

[Kathryn Moore Lab @KathrynMooreLab]

So fun to collaborate with @GiannarelliL on this! This discovery opens new possibilities for understanding cardiovascular risks in cancer survivors and the role of immune checkpoints in atherosclerosis 🎯 @ICOSociety @CardioOncology

[Kathryn Moore Lab @KathrynMooreLab]

🚨 New discovery alert! 🚨
In this month’s issue of @NatureCVR, we identify a dendritic cell population that acts as a hub for immune checkpoint communication within human atherosclerotic plaques. @NYULHCVRC @ChiaraGiannare1
https://t.co/aBk1GhsPFO

[Kathryn Moore Lab @KathrynMooreLab]

FASCIN1+ DCs in mouse and human plaques are a key target of immunotherapies linked to accelerated atherosclerotic plaque progression and increased risk of stroke and myocardial infarction in cancer survivors. #CardioOncology

[Kathryn Moore Lab @KathrynMooreLab]

We’re proud to be #1 in New York for Cardiology, Heart & Vascular Surgery, according to U.S. News & World Report! @nyugrossman @NYULHCVRC

[Kathryn Moore Lab @KathrynMooreLab]

Honored to receive the Grand Prix Scientifique of the Fondation Lefoulon-Delalande - @InstitutFrance with Chris Glass.

[Dr. Mona Nemer @ChiefSciCan]

Thrilled to see the outstanding contributions of the 2 recipients of the @InstitutFrance Grand Prix Scientifique Lefoulon Delalande — one of the 🌎 most important prizes in #CardiovascularResearch. So proud to see 🇨🇦 scientist @KathrynMooreLab up there!

[Kathryn Moore Lab @KathrynMooreLab]

Very proud of my amazing team! ⁦@aacnewman13⁩ ⁦@ycyr06⁩

[Kathryn Moore Lab @KathrynMooreLab]

Fantastic talk by ⁦⁦@GiannarelliL⁩ on #Atherosclerosis in the COVID era. #VascularDiscovery24

[Kathryn Moore Lab @KathrynMooreLab]

What a fantastic meeting! #VascularDiscovery24 community is the best.

[Dr. Cristina Espinosa-Diez 👩🏼‍🔬🧬☕️🐈‍⬛🐈 @Krispy_ed]

Closing the session with reverse #CardioOncology with Richard Von Itter from @KathrynMooreLab #VascularDiscovery24 @AHAScience

[Kathryn Moore Lab @KathrynMooreLab]

Check out Poster #2007 at #VascularDiscovery24 to learn how ischemic injury accelerates breast cancer. @aacnewman13

[Kathryn Moore Lab @KathrynMooreLab]

Big day for MooreLab at #VascularDiscovery24! @FazliBozal is competing for the Investigator in Training Award & @aacnewman13 for Emerging Scientist Award for Women Award. 🤞

[Kathryn Moore Lab @KathrynMooreLab]

I am honored to share the @InstitutFrance Grand Prix Scientifique de la Fondation Lefoulon-Delalande with Chris Glass (UCSD). Merci!

[NYU CVRC @NYULHCVRC]

Director of the CVRC, Kathryn Moore wins prestigious Grand Prix Scientifique de la Fondation Lefoulon- Delalande. https://t.co/9T2b8zL9gi

[Mireille Ouimet @MireilleOuimet]

Beyond excited that @KateyRayner was appointed to be the next CSO of the @HeartInstitute! In addition to being a stellar scientist, a tremendous colleague & leader in cardiovascular research, this is also a historical moment b/c she will be the first woman CSO at our institute!

[Kathryn Moore Lab @KathrynMooreLab]

We show the therapeutic potential of 4-OI for reducing CVD inflammation in humans through CyTOF and scRNAseq using a systems immunology approach (5/5)

[Kathryn Moore Lab @KathrynMooreLab]

Using mouse models of Irg1 deficiency, we show that loss of this pathways aggravates atherosclerosis, increasing plaque size, macrophage content, and inflammatory signaling including IL-1b (2/5)

[Kathryn Moore Lab @KathrynMooreLab]

Treatment of mice with advanced atherosclerosis using an itaconate derivative, 4-OI, led to beneficial plaque remodeling, highlighting its potential as a novel therapeutic strategy (4/5)

[Kathryn Moore Lab @KathrynMooreLab]

We show that the enzyme IRG1/ACOD1, responsible for producing the immunomodulatory metabolite itaconate, is expressed in human and mouse atherosclerotic plaques. Intriguingly, its expression decreases with disease progression suggesting loss of this protective mechanism (1/5)